A negative-pressure cup structure includes a negative-pressure cup body and a light therapy module. The negative-pressure cup body has a rim. The light therapy module is received in the negative-pressure cup body and includes a circuit board and multiple light-emitting diodes (LEDs) mounted on the circuit board and irradiating corresponding to the rim. Therefore, the negative-pressure cup structure further has functions of light therapy and skin care.

An anti-oxidizing agent or skin stress suppressing agent was provided with.

An anti-oxidizing agent or skin stress suppressing agent comprising a wavelength conversion substance as an active ingredient; a composition and a product comprising the anti-oxidizing agent or skin stress suppressing agent; and a method for suppressing oxidization and skin stress of skin using thereof were provided with. The present invention can exhibit a desirable effect on skin by effectively making use of ultraviolet light to suppress skin cells.

The present invention is directed to a tandem-structured bio-organic light emitting diode (bio-OLED) for photodynamic therapy, and to a photodynamic therapy device including the same to convert a red light emitted from the bio-organic light emitting diode into a near-infrared light (NIR) emission, thereby enabling the use of a PBM therapy in a wide wavelength range of 600 to 1,000 nm.

A sheet-shaped oral appliance is provided that is detachably attached to an oral body device and includes a functional portion with a sensor unit that acquires information in an oral cavity and an energy irradiation unit that radiates energy into the oral cavity, an electrical connection portion, and a wiring portion that connects at least one of the sensor unit and the energy irradiation unit to the electrical connection portion. The functional portion, the connection portion, and the wiring portion are formed by a wiring layer having first and second main surfaces that oppose each other, a first insulating layer arranged on the first main surface and a second insulating layer arranged on the second main surface. Moreover, in the functional portion, a thickness of the first insulating layer is smaller than a thickness of the second insulating layer.

Provided are a brain stimulation system, method, apparatus and storage medium based on artificial intelligence. The system includes: a plurality of brain stimulation terminals and a cloud platform. The cloud platform is configured to, with artificial intelligence algorithm especially machine learning and deep learning, generate multi-dimensional psychological big data using physiological data and psychological state evaluation parameters gotten from the plurality of brain stimulation terminals and established models of algorithm for disease diagnosis. The brain stimulation terminal is configured to analyze the physiological data and psychological state evaluation parameters of a target subject, measure a mental state of the target subject, obtain brain stimulation parameters required for the target subject according to the mental state, and generate corresponding non-invasive brain stimulation for the target subject according to the brain stimulation parameters based on the multi-dimensional big data through the artificial intelligence algorithm.

Systems and methods for treating sexual dysfunction using transcranial photobiomodulation (t-PBM) with near infrared light (NIR) are provided. In particular, a device configured for treating a disorder of a subject, the device can have a power source and a light source configured to receive power from the power source to cause the light source to emit near infrared light, wherein the near-infrared light has a wavelength of 600 nm to 1400 nm. The device has a processor and a housing configured to position the light source to deliver the near infrared light to a region of interest of the subject via transcranial photobiomodulation in a dosimetry and duration sufficient to treat the disorder.

A phosphor-containing drug activator activatable from a Monte Carlo derived x-ray exposure for treatment of a diseased site. The activator includes an admixture or suspension of one or more phosphors capable of emitting ultraviolet and visible light upon interaction with x-rays, wherein a distribution of the phosphors in the diseased target site is based on a Monte Carlo derived x-ray dose distribution. A system for treating a disease in a subject in need thereof, includes the drug activator and a photoactivatable drug, one or more devices which infuse the photoactivatable drug and the activator including the pharmaceutically acceptable carrier into a diseased site in the subject; and an x-ray source which is controlled to deliver the Monte Carlo derived x-ray exposure to the subject for production of ultraviolet and visible light inside the subject to activate the photoactivatable drug and induce a persistent therapeutic response, the dose comprising a pulsed sequence of x-rays delivering from 0.5-2 Gy to the tumor.

The present subject matter is directed to a luminogen exhibiting aggregation induced emission, wherein T1, T2, and T3 comprise one or more polyynes as a conjugated bridge. The present subject matter is also directed to an AIEgen comprising a hydrophilic pyridium group as a strong electron-withdrawing group; a piperazine group as an electron-donating group; and a α-Cyanostilbene; wherein the AIEgen exhibits aggregation induced emission. The present subject matter is directed to a method of synthesizing an AIEgen and is further directed to a method of labeling comprising incubating a subject having cells with a conjugate formed by conjugating an AIEgen with an antibody; and selectively labeling desired cells by turn-on imaging, wherein labeling occurs when the desired cells are selectively stained by fluorescent emission of the AIEgen upon degradation of the antibody after cellular internalization of the conjugate through endocytosis.

The present subject matter is directed to a luminogen exhibiting aggregation induced emission, wherein T1, T2, and T3 comprise one or more polyynes as a conjugated bridge. The present subject matter is also directed to an AIEgen comprising a hydrophilic pyridium group as a strong electron-withdrawing group; a piperazine group as an electron-donating group; and a α-Cyanostilbene; wherein the AIEgen exhibits aggregation induced emission. The present subject matter is directed to a method of synthesizing an AIEgen and is further directed to a method of labeling comprising incubating a subject having cells with a conjugate formed by conjugating an AIEgen with an antibody; and selectively labeling desired cells by turn-on imaging, wherein labeling occurs when the desired cells are selectively stained by fluorescent emission of the AIEgen upon degradation of the antibody after cellular internalization of the conjugate through endocytosis.

A phototherapy treatment apparatus and methods are provided. In particular, the present disclosure provides a phototherapy treatment apparatus configured to diffusely transmit light emitted from a light source to a patient.